ASM Global’s AO Arena in Manchester Unveils Dramatic Multimillion Dollar Three-Year Reimagination of Legendary Venue
27.4.2022 20:05:00 EEST | Business Wire | Press release
ASM Global, the world’s leading producer of entertainment experiences, venue management and event strategy, has announced a $63 million plan beginning this summer to transform the AO Arena in Manchester. This plan is set to dramatically enhance the venue’s premier position for live entertainment experiences through state-of-the-art infrastructure expansion and innovative guest features as the iconic arena looks to the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427005883/en/
AO Arena, Manchester (Photo: Business Wire)
AO Arena in Manchester, located in the heart of the city, is one of the busiest indoor arenas in the world. Through its near 30-year history, the venue has firmly established itself as a beloved and iconic Manchester landmark, a must-play for artists, and a fan-favorite destination for world-class live entertainment. Officials from the AO Arena will be releasing more detailed plans in coming months.
Chris Bray, EVP Europe at ASM Global, said, “AO Arena is one of the world’s iconic venues and a much-loved part of Manchester’s rich culture and history. It has been delivering world-class entertainment experiences for over two decades. As we approach our 30th anniversary, this ambitious endeavor will not only reinforce its position as a leading destination for live entertainment but will extend its market leadership for ‘live’ and fan experiences for the next 30 years. We’re proud to be further investing into the heart of Manchester.
“The first phase will enhance and increase our standing floor capacity to share this historic arena with even more of our guests, and we will also be adding new hospitality lounges and investing in delivering an upgraded concourse experience. Our performers will be immersed in an all-new, back-of-house artists’ campus, unparalleled anywhere.”
Additional major developments include new arena entrances welcoming guests to the venue and new premium seating, which will transform the venue to an elevated experience.
AO Arena’s back-of-house campus dramatic upgrade will include a complete overhaul of the backstage experience for artists, production and crew. This includes new artist dressing rooms and production areas, a world-class green room with meet-and-greet facilities, an overhaul of crew catering, and first-class connectivity and technology.
Plans have already been jump started by the venue’s rapid scheduling of major sell-out 2022 events, including Billie Eilish, Dua Lipa, Diana Ross, Alicia Keys, Swedish House Mafia, Snoop Dogg, George Ezra and more.
Jen Mitchell, general manager at the AO Arena, said, “This is a really exciting time for AO Arena. Not only are we able to welcome guests back after a challenging two years with a program packed full of world-class acts and entertainment, now we can reveal the first phase of ASM Global’s plans for the arena’s redevelopment. This will enhance the experience for everyone who sets foot in the venue, including artists, production, crew and our staff who work so hard to make the magic happen right here in Manchester.”
Unveiled in 1995, the arena was the first indoor venue in the U.K. to be built with a layout of 360-degree seating. Attracting over 1 million visitors yearly, the 21,000-capacity arena is a winner of the Stadium Business Awards’ prestigious ‘Venue of the Year’ award. There has been a host of musical talent that has performed at the venue, from Led Zeppelin legends Jimmy Page and Robert Plant, The Rolling Stones and Pavarotti to Dua Lipa and Lady Gaga as well as Manchester’s homegrown artists including Take That, Oasis, Elbow, New Order and The Courteeners. The venue has hosted everything from the 2002 Commonwealth Games, 2008 FINA World Swimming Championships and international boxing bouts by Mike Tyson, Anthony Joshua, Tyson Fury, David Haye, Joe Calzaghe and local champions Ricky Hatton, Amir Khan and Anthony Crolla.
About ASM Global
ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management—delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents, with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibition centers, and performing arts venues. Connect with us on LinkedIn, Facebook, Instagram and Twitter. asmglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005883/en/
Contact information
Jim Yeager
breakwhitelight (for ASM Global)
jim@breakwhitelight.com
Mobile: 1-818-264-6812
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
Andersen Global Adds Depth to Tax and Global Mobility Capabilities in Germany30.6.2026 16:30:00 EEST | Press release
Andersen Global strengthens its presence through a Collaboration Agreement with Lohr and Company (L+C), a senior-led tax advisory platform, providing practical, responsive solutions in tax compliance, cross-border tax, global mobility, and transfer pricing. Headquartered in Germany with a presence in Austria, L+C advises large multinationals and family-owned companies, family offices, foundations, and high-net-worth individuals. The firm, founded in 2001, specializes in areas such as global mobility, M&A, international tax law, country-by-country reporting, and transfer pricing, including Pillar 2 reporting. Additionally, L+C supports clients with trusts and foundations, tax compliance, payroll and financial accounting, and private financial advisory services. “Collaborating with Andersen Global represents an important step in expanding our international capabilities and strengthening the value we provide to clients navigating increasingly complex cross-border matters,” said Jörg-Andre
90% of IT Leaders See Gaps in AI Threat Readiness, Lenovo Brings Single Point of Accountability to Cyber Resiliency30.6.2026 16:00:00 EEST | Press release
As organizations accelerate AI adoption and digital workplace transformation, many are finding that cyber resilience is undermined not by a lack of security tools, but by growing operational complexity and threat sophistication. According to recent research, 90% of IT leaders acknowledge gaps in their ability to defend against AI-driven threats. While security investments continue to grow, many organizations face a different challenge: fragmented accountability. Security operations remain highly distributed and siloed, making it increasingly difficult to coordinate response efforts, maintain end-to-end business continuity, and recover quickly when incidents occur. To help organizations address this challenge, Lenovo is expanding its global Security Services portfolio with a revamped cyber resiliency framework and end-to-end security offerings designed to provide a single point of accountability, help organizations reduce security complexity, cut system downtime by up to 50%, and lower
SC Therapeutics Initiates REACH2 Trial for Refractory Chronic Cough30.6.2026 16:00:00 EEST | Press release
SC Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies that deactivate mechano-sensitive ion channels (MSCs) to treat respiratory and cardiovascular disease, today reports initiation of the REACH2 trial. The study will evaluate the Company's lead product candidate in patients with refractory chronic cough (RCC) – a debilitating condition for which no disease-modifying treatment options currently exist. The trial will be run in three major cough centers across the UK. A Novel, Disease-Modifying Mechanism of Action SC0032, SC Therapeutics' most advanced product candidate, is a proprietary therapeutic aerosol composed entirely of ions endogenous to human airways. Unlike current symptomatic investigational drugs – including P2X3 receptor antagonists and neurokinin-1 (NK1) receptor antagonists that seek to dampen neural hypersensitivity through receptor blockade – SC0032’s approach directly addresses the upstream inflammatory drivers of chronic cough. By acting to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom